Author:
Dong Chao,Yang Runxiang,Li Hongjian,Ke Kunbin,Luo Chunxiang,Yang Fang,Shi Xi-Nan,Zhu Ying,Liu Xu,Wong Man-Hon,Lin Guimiao,Wang Xiaomei,Leung Kwong-Sak,Kung Hsiang-Fu,Chen Ceshi,Lin Marie Chia-mi
Publisher
Springer Science and Business Media LLC
Reference51 articles.
1. Dizon, D. S. et al. Clinical Cancer Advances 2016: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. J Clin Oncol 34, 987–1011, https://doi.org/10.1200/JCO.2015.65.8427 (2016).
2. Samuels, Y. & Waldman, T. Oncogenic mutations of PIK3CA in human cancers. Curr Top Microbiol Immunol 347, 21–41, https://doi.org/10.1007/82_2010_68 (2010).
3. Karakas, B., Bachman, K. E. & Park, B. H. Mutation of the PIK3CA oncogene in human cancers. Br J Cancer 94, 455–459, https://doi.org/10.1038/sj.bjc.6602970 (2006).
4. Dy, G. K. et al. Epidemiology of Pi3k Pathway Alterations in Patients with Metastatic Non-Small Cell Lung Cancer (Nsclc): Findings from the International Basalt-1 Study. Journal of Thoracic Oncology 8, S145–S146 (2013).
5. Yamamoto, H. et al. PIK3CA mutations and copy number gains in human lung cancers. Cancer Res 68, 6913–6921, https://doi.org/10.1158/0008-5472.CAN-07-5084 (2008).
Cited by
13 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献